News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India
The hospital has taken a huge step by offering “Titli-palliative care services at home” to provide curative, restorative, and life-prolonging treatment to seriously ill children
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
The move will add new global talent to Cytel’s Strategic Consulting group
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Subscribe To Our Newsletter & Stay Updated
